HDFC Securities has come out with its fourth quarter (Jan-March’ 18) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Glenmark Pharma to report net profit at Rs. 170 crore up 711.4% year-on-year (up 83.2% quarter-on-quarter).
Net Sales are expected to decrease by 15 percent Y-o-Y (down 5.1 percent Q-o-Q) to Rs. 2,060 crore, according to HDFC Securities.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 32.8 percent Y-o-Y (up 14.8 percent Q-o-Q) to Rs. 330 crore.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
HDFC Securities Q4 Preview - Pharmaceuticals
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
